
EFSA has given its safety opinion on S-acetyl glutathione as a novel food. An opinion is not an authorisation, and the months still to run before the implementing act are the best window you will get to decide the product.
Three numbers a formulation is designed around: adolescents from 10 years and adults, up to 300 mg per day, in food supplements and foods for special medical purposes. The draft opinion was in public consultation between 19 September and 10 October 2025.
EFSA assesses; it does not authorise. Authorisation comes when the Commission adopts the implementing regulation adding the ingredient to the Union list. EFSA has nine months to deliver its opinion once the application is forwarded, the Commission then seven months from the opinion to table the act: legal deadlines, not promises, but they give a horizon. And listing is normally generic — once authorised, any operator may use the ingredient under the stated conditions, unless the applicant obtained data protection.
They are different molecules and distinct regulatory objects: what holds for one says nothing about the other. A supplier who uses the two names interchangeably on a technical data sheet is telling you how carefully they read a specification.
In a supplement this ingredient will not work alone. The strongest commercial target today is the antioxidant and healthy-ageing shelf, adults from 35: it is the largest slice of the category and the easiest positioning to defend, because the health claim — when there is one — comes from the authorised nutrient beside it.
That target narrows the shortlist of second actives: vitamin C, vitamin E, L-selenomethionine, zinc. And what decides the product is not whether the single ingredient works, but whether the pairing does more than the sum of its parts, at which ratio and through which mechanism. That question is answered in cells, comparing pairings against each other.
Compatibility is not a given, and it often depends on the chemical form rather than the substance.
S-acetyl glutathione has its thiol protected and is therefore more stable than the reduced form, but the free fraction still reacts: the care points stand.
On this shelf very few products will ever see a clinical study: the claim, when there is one, comes from the authorised nutrient and not from a trial of yours. Which means the in vitro work is not the step before the evidence: it is the evidence you will have. It is what tells you which pairing actually does something, and what carries your technical file in front of a buyer.
Before that comes the read-out: the endpoint has to discriminate — move with dose, separate the pairing from the single ingredient, repeat across independent experiments. A read-out that separates nothing in vitro will separate nothing in ninety subjects either. And for the few that do reach the clinic, it is exactly what makes the study test the right hypothesis instead of four.
In vitro does not substantiate a health claim: it substantiates your choice. Alongside it, the less visible part — characterising the ingredient as it arrives and as it survives your process.
The EFSA opinion is a safety assessment, not an authorisation: that comes when the Commission adopts the implementing regulation adding it to the Union list.
Adolescents from 10 years and adults, up to 300 mg a day, in food supplements and foods for special medical purposes.
Technical content and news from our laboratories, sent when there is something worth saying.